Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Esperion Therapeutics (United States), United States, covering academic research published from 2000 to 2023. Read More.
Open Access Percentage
51%
Total
Publications
158
Total Open
Publications
81
Total
Citations
11K
Open Access
Percentage
51%
Total
Publications
158
Total Open
Publications
81
Total
Citations
11K
Breakdown
Publisher Open
22%
Both
25%
Other Platform Open
4%
Closed
49%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 16%
12
Hybrid 64%
47
No Guarantees 20%
15
Other Platform Open
Domain 74%
34
Other Internet 20%
9
Institution 15%
7
Preprint 11%
5
Public 2%
1
Other Platform Locations
Name | Platform Type | Publications |
---|---|---|
PubMed Central | Domain | 34 |
Europe PMC | Domain | 15 |
DOI | Other Internet | 4 |
medRxiv | Preprint | 3 |
Universita Degli Studi Di Milano - Archivio Istituzionale della Ricerca | Institution | 2 |
Imperial College London - Spiral | Institution | 2 |
bioRxiv | Preprint | 2 |
Washington University School of Medicine - Digital Commons@Becker | Institution | 1 |
UWA - UWA Profiles and Research Repository | Other Internet | 1 |
Unknown Repository | Other Internet | 1 |